The pan-Canadian Pharmaceutical Alliance (pCPA) may not be known to many Canadians but, nonetheless, so many Canadian patients are impacted by their work in profound ways. Last week, my colleague, Mark Smithyes, MBA joined the pCPA's CEO, Douglas Clark, in a discussion that touched on the challenges of improving access for patients to new and innovative medicines while supporting payors' interests in optimizing value in drug spending.
In many ways, Canada has been a leader in examining this question of "value", particularly our early leadership in embracing the Health Technology Assessments (HTA) framework and, later, in pioneering Product Listing Agreements (PLA) that, together, look beyond the question of PRICE and go deeper into an appreciation of VALUE, both to patients and health systems alike. This has not been easy, and challenges remain, but I have to say that there have been some amazing examples of how industry, payors, governments have been able to bring innovation and goodwill to the table in the interests of finding common ground and finding the "win" for patients. No doubt, serious challenges lie ahead, but the willingness of actors like Douglas Clark and others to speak openly and frankly about those challenges at a forum like this is not only a positive sign, but also speaks volumes about the kind of unique ecosystem that Canada -- and Canadians -- have painstakingly created over the years.
Delphic Research's Health and Life Sciences practice Director, Mark Smithyes, led an engaging discussion with the pCPA's CEO, Douglas Clark, on the organization's strategic directions and on the challenges faced by both payors and industry on improving patients' access. The "fireside chat" was a highlight of the Canadian Institute's Pathway to Access summit held in Toronto last week.
VP Leader Market FL
2wEric, as always such an important talks. Hello from Miam. Arch Staffing